Traditional Chinese medicine injections with activating blood circulation, equivalent effect of anticoagulation or antiplatelet, for acute myocardial infarction

A protocol for the systematic review and meta-analysis of randomized clinical trials

Xiang Li, MD, Yan Lou, MD, Ju-Ju Shang, MD, Hong-Xu Liu, MD, Jia-Ping Chen, MD, Hui-Wen Zhou, MD

Abstract

Background In spite of a growing number in the use of percutaneous coronary intervention (PCI) in China, the mortality of acute myocardial infarction (AMI) has not decreased. Traditional Chinese medicine injections for Activating Blood Circulation (TCMi-ABC), equivalent effect of anticoagulation or antiplatelet, are widely used in China; however, the improvement of fatality towards AMI is unclear. Therefore, we intend to conduct a systematic review and meta-analysis to evaluate the efficacy and safety of TCMi-ABC in treatment with AMI.

Methods Based on the “National Medical Products Administration of China,” TCMi-ABC with AMI treatment indication will be selected, including Danhong injection, Sodium Tanshinone IIA Sulfonate injection, Danshen Chuanxiongqin injection, and Puerarin injection. Randomized controlled studies will be searched from as follows: PubMed, Embase, the CENTRAL in Cochrane Library, Chinese Biomedical Literature Database (SinoMed), China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP), and Wanfang Data Knowledge Service Platform. Two researchers will work independently on literature selection, data extraction, and quality assessment. The outcomes focus on the effects of TCMi-ABC on fatality of patients with AMI in hospitalization and in the long term, the incidence of malignant arrhythmia, left ventricular ejection fraction, and adverse events. RevMan 5.4.1 software was used for meta analysis.

Results This study will conduct a comprehensive literature search and provide a systematic synthesis of current published data to explore the efficacy and safety of TCMi-ABC for AMI.

Conclusion This study will provide high-quality evidence for treatment of AMI with TCMi-ABC in terms of efficacy and safety, which may help clinicians make a better complementary treatment schedule of patients with AMI.

Abbreviations: AMI = acute myocardial infarction, PCI = percutaneous coronary intervention, TCMi-ABC = Traditional Chinese medicine injections for Activating Blood Circulation.

Keywords: activating blood circulation, acute myocardial infarction, protocol, systematic review, Traditional Chinese medicine injections
1. Introduction

1.1. Description of the condition

Global Burden of Disease Study 2019 showed that acute myocardial infarction (AMI) was one of the major diseases with high global morbidity and mortality, causing a huge global economic and medical burden,[1] which was also reflected in China. According to the “Report on Cardiovascular Health and Diseases Burden in China: an Updated Summary of 2020,” the overall mortality of AMI in China from 2002 to 2018 showed an upward trend, especially a rapid increase in 2005.[2] Recently, overall mortality of AMI in China from 2002 to 2018 showed an upward trend, especially a rapid increase in 2005.[2] Recently, percutaneous coronary intervention (PCI) in China has been rapidly developed in China, as is reported that the number of cases of PCI in China received more than 915,000 in 2018, which had surpassed the United States and ranked first in the world. But China PEACE Studies[3] showed that in China the hospital fatality of AMI has not decreased significantly as the growing development of PCI. In addition to popularizing secondary prevention of coronary heart disease actively and promoting early reperfusion treatment of AMI, whether traditional Chinese medicine (TCM) as a complementary method can be beneficial in reducing the fatality of patients with AMI has received more and more attentions, especially since artemisinin was recognized as a clinical value of these TCM-ABC interventions for AMI on the basis of the current standardized Western medicine treatment.

TCM has a history of treating AMI for more than 2000 years. Translating the “experience” of TCM in treatment with AMI into “evidence” is regarded as a key step to help more patients with AMI to get clinical benefits. In the 1970s, Professor Ke-Ji Chen discovered a type of Chinese medicine with function of antiocoagulant and antiplatelet on the basis of reading a large number of ancient Chinese medicine books, which calls “Activating Blood Circulation (ABC)” drugs, can play a role in myocardial protection. In the 1980s, Professor Chen conducted a first evaluation of Chinese medicine formulae with function of ABC called Guanxin No. 2 in treatment with stable angina by a multicenter, randomized, double-blind, placebo-controlled clinical trial, which showed that Guanxin No. 2 had myocardial protective effects including relieving angina, improving myocardial ischemia and abnormal hemorhoemology.[4] As the research went on, it has gradually been discovered that the “ABC” drugs with equivalent effects of anticoagulant and antiplatelet can be beneficial in reducing the incidence of cardiovascular events and the risk of restenosis in coronary stents.[5,6] At present, “ABC” drugs have become the most commonly used Chinese herbal medicine for coronary heart disease in Chinese mainland.

1.2. Description of the intervention

Strategies of western medicine in treatment with AMI include general treatments, reperfusion therapy, and drug therapy. General treatments refer to measures such as monitoring of vital signs, relief of pain, breathing difficulties and anxiety, and improvement of hypoxia. Drug treatment mainly includes antiplatelet aggregation drugs, anticoagulant drugs, lipid-lowering drugs, β-receptor blockers, calcium channel blockers, nitrate drugs, angiotensin converting enzyme inhibitors or angiotensin II receptor. Reperfusion therapy is achieved through PCI and thrombolyis and coronary artery bypass surgery.[7] Besides the current standardized Western medicine treatment, Traditional Chinese medicine injection (TCMI), as a complementary and alternative treatment, may play a positive role in further reducing the fatality of AMI.[3] TCMI is a sterile preparation for injection after extraction and purification from traditional Chinese medicine.[8] It is a new dosage form combined with TCM theory and modern pharmaceutical technology, which is widely used in China.[9] The world’s first TCMI, Bupleurum injection, came out in 1941 and has a history of 80 years. Currently, there have been 134 kinds of TCMI on the market in China,[10] in which also play an important role in the treatment of AMI.[11] A survey involving more than 5000 AMI patients in 26 Level three Class A TCM hospitals in China during 10 years period from 1999 to 2008 showed that TCMI had the potential to reduce the fatality of AMI patients,[12,13] but lack of high-level evidence.

To seek high-level evidence for the efficacy and safety of Traditional Chinese medicine injections for Activating Blood Circulation (TCMi-ABC) in treatment with AMI, firstly we searched information about TCMi-ABC with indications for the treatment of AMI on the data platform of “National Medical Products Administration of China” (https://www.nmpa.gov.cn/). The search results included Dansheng injection, Tanshinone II A sodium sulfonate injection, Danshen ligustrazine injection, and puerarin injection. We will evaluate the clinical value of these TCM-ABC interventions for AMI on the basis of the current standardized Western medicine treatment.

1.3. How the intervention might work?

Dansheng injection (DHI) is an injection made from two Chinese herbal medicines: carthami flos and salvia miltiorrhiza bunge. Tanshinone II A sodium sulfonate injection (TIIaI) is an effective compound extracted from an herb medicine called Salvia Miltiorrhiza. Danshen ligustrazine injection (DLI) is a compound injection composed of Salviae miltiorrhizae extract and ligustrazine hydrochloride monomer. Puerarin injection (PI) is an isoflavon compound extracted from an herb medicine called Pueraria lobata. Experimental studies have demonstrated these four TCMi-ABCs with multiple cardiac-protective effects on AMI, including prevention of ischemia reperfusion injury, improvement of myocardial metabolism, reduction of myocardial infarction area and functions of anti-oxidant stress and anti-inflammatory damage.[14-27]

1.4. Why it is important to do this review?

TCM-ABC is widely used in China in treatment of coronary artery disease (CAD). As shown in previous researches, these four TCMi-ABCs with indications for the treatment of AMI can be used as a complementary method to play a role on myocardial protection. However whether they can safely and effectively reduce the fatality of AMI patients is still controversial. It is worth noting that a recent retrospective investigation conducted in mainland China suggested that TCMI had not been found benefits in the application of acute heart failure patients with CAD. On the contrary, salvia miltiorrhiza bunge, one of the most commonly used drugs for ABC in the treatment of AMI, had been found to increase the risk of bleeding in patients.[28] Therefore, it is necessary to carry out a systematic review of the efficacy and safety of TCMi-ABC in treatment with AMI based on the current original research.

1.5. Objectives

To systematically evaluate the efficacy and safety of TCMi-ABC for AMI.
2. Methods

2.1. Study registration

The protocol was registered on INPLASY (https://inplasy.com/inplasy-2021-7-0082/) and its registration number was INPLASY202170082. We will complete this protocol according to the preferred reporting items for systematic reviews and meta-analysis protocols. The changes are described in our full review if needed.

2.2. Ethic approval

Ethical approval will not be necessary since this systematic review and meta-analysis only uses published papers, which will not reveal personal privacy and violate human rights.

2.3. Inclusion criteria for study selection

2.3.1. Types of studies. Only randomized controlled trials can be included in our research, case reports, animal experiments, and reviews will be excluded, and there will be no language restrictions in the selection of literature.

2.3.2. Types of patients. Regardless of their nationality, age, race, patients who meet the diagnostic criteria for AMI will be included as participants.

2.3.3. Types of interventions. The experimental group was treated with one of these four TCMi-ABCs (including DHI, Tiliail, DLL, and Pl) on the basis of western medicine treatment. The control group was treated with Western medicine treatment alone or combined with placebo. Western medicine basis treatments include: general treatment (including vital signs monitoring, symptom relief, etc), reperfusion therapy (including PCI, thrombolytic therapy, and coronary artery bypass grafting), drug therapy (including: antiplatelet, anticoagulant, lipid-lowering, etc). TCMi-ABC was the only intervention difference between the control group and the experimental group in all studies.

2.3.4. Types of outcome measures. The outcomes focus on the effects of TCMi-ABC on fatality of patients with AMI in hospitalization and in the long term. The long-term fatality refers to the fatality of AMI 1 year or more after the disease. The other outcomes include the incidence of malignant arrhythmia, left ventricular ejection fraction (LVEF), adverse events (such as nausea, dizziness, and vomiting). The included studies reported at least one of the above outcomes.

2.4. Exclusion criteria

(1) Diagnostic criteria were not mentioned or unclear in the literature.
(2) The clinical trial control setting is unreasonable or does not meet the requirements of this study, such as the combination of other Chinese patent medicine in the control group.
(3) Duplicate publications.
(4) Literatures for the required effect indicators are not included.

2.5. Search methods for identification of studies

2.5.1. Electronic searches. The search terms and strategy described in Additional File 1 will be used to search the following databases: PubMed, Embase, the CENTRAL in Cochrane Library, Chinese Biomedical Literature Database (SinoMed), China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP), Wanfang Data Knowledge Service Platform. All database retrieval times are selected from the date of database establishment. Taking PubMed as an example, the initial search strategy is shown in Table 1, which will be adjusted according to the specific database.

2.5.2. Searching other resources. In addition to the literatures retrieved from the electronic databases, our study will also search for literatures whose titles may be relevant about it in the bibliography attached to the included literatures. Paper books and journals related to our study will be manually reviewed to ensure that the included literature is comprehensive. Related ClinicalTrials will also be searched at “ClinicalTrials.gov.” to determine whether any literatures to be published met the inclusion criteria.

2.6. Search methods for identification of studies

2.6.1. Selection of studies. Each step of the literature search will be performed independently by 2 reviewers according to the established search rules. After screening based on the inclusion criteria, 2 reviewers (JPC and HWZ) will exclude the papers that do not meet the inclusion criteria by reading the titles and abstracts. Then, the reviewers will check the full texts to

| Table 1 |
| --- |
| Table 1: Search strategy of the PubMed. |

| Search | Query |
| --- | --- |
| #1 | Myocardial infarction[MeSH] |
| #2 | Myocardial infarction OR acute myocardial infarction OR AMI OR infarction, myocardial OR cardiovascular stroke OR infarctions, myocardial OR myocardial infarctions OR cardiovascular strokes OR heart attack OR strokes, cardiovascular OR myocardial infarct OR infarct, myocardial OR stroke, cardiovascular [Title/Abstract] |
| #3 | #1 OR #2 |
| #4 | Injection[Mesh] |
| #5 | Injection OR injectables OR injectable OR injections[Title/Abstract] |
| #6 | #4 OR #5 |
| #7 | Puerarin OR Danhong OR Dan red OR Sulfotanshinone sodium OR Sodium Tanshinone IIA Sulfonate OR Tanshinone Ila OR Salviae miltiorrhizae and ligustrazine hydrochloride injection OR Danshen Chuanxiongqin[Title/Abstract] |
| #8 | Randomized controlled trial[publication type] OR Controlled Clinical Trial[Publication Type] OR random*[All Fields] |
| #9 | #3 AND #6 AND #7 AND #8 |

AMI = acute myocardial infarction.
determine the final decision according to the criteria. If the articles information is insufficient, we will try to contact the authors to obtain the necessary details. When 2 reviewers have different opinions, the final decision will be made by the third reviewer (YL). The selection flow process of is shown in the preferred reporting items for systematic reviews and meta-analysis flow chart (Fig. 1).

2.6.2. Data extraction and management. First we design an extraction form that meets the purpose of this system review, which will include the following information from the included studies: participant characteristics, interventions, outcomes, and adverse events. Two investigators (JPC and HWZ) independently completed the data collection form for all eligible studies. The corresponding authors will be contacted to request insufficient or missing information. Disagreements will be resolve by discussion or by appealing to a third author (YL). The data were stored in Microsoft Excel.

2.6.3. Assessment of risk of bias in included studies. We will use the Cochrane risk assessment tool to assess the risk of bias. The methodological quality of RCTs will be independently evaluated by 2 reviewers (JPC and HWZ). The following 7 items will be included: random sequence generation, allocation concealment, blinding of participants and caregivers, blinding of outcome evaluator, incomplete outcome data, selective reporting, and other bias. High, low, and unclear assessments will be performed for each item. Any disagreement between the 2 reviewers (JPC and HWZ) will be resolved by a discussion. Further disagreements will be arbitrated by the third author (YL).

2.6.4. Measures of treatment effect. We will use the mean difference or standard mean difference with 95% confidence intervals as the effect measure for continuous data. Dichotomous outcomes will be analyzed by the risk ratio with 95% confidence interval.[30]

2.6.5. Dealing with missing data. When there are events in the reports that are unclear or do not report data, we will contact the author by phone or email to obtain complete information.[31]

2.6.6. Assessment of heterogeneity and data synthesis

2.6.6.1. Assessment of heterogeneity. We will use RevMan 5.4.1 software to detect the heterogeneity between studies. When $P < .01$, $I^2 > 50\%$, there is significant heterogeneity between studies; otherwise, heterogeneity is acceptable.
2.6.8. **Subgroup analysis.** We will then acquire a stable result of our study.

2.6.9. **Assessment of reporting biases.** Funnel plots were used to explore the publication bias when 10 or more trials were included.

2.6.10. **Grading the quality of evidence.** The certainty of a body of evidence will be assessed by using the approach developed by the Grades of Recommendation, Assessment, Development and Evaluation Working Group, involving risk of bias, heterogeneity, indirectness, imprecision, publication bias, and other domains. The certainty level will be rated as high, moderate, low, or very low, and the strength of evidence recommendation will be judged as strong or weak.

### 3. Discussion

Our systematic review will review the efficacy and safety of TCMi-ABC in the treatment of AMI comprehensively. The evidence from this review may benefit patients with AMI and clinicians, which will also help the formulation of relevant clinical guidelines. However, if there is a large degree of heterogeneity in method quality and outcome measurement, it may cause some challenges to the research results.

### Author contributions

XL and YL drafted the protocol. XL and JJS designed the search strategy. YJJ and HXL provided statistical expertise. JJS read, provided feedback, and approved the final manuscript. JPC, HWZ, and YL reviewed and revised the manuscript. All authors have read and approved the final version of the manuscript.

### Data creation: Jia-Ping Chen, Hui-Wen Zhou.

### Funding acquisition: Ju-ju Shang.

### Methodology: Hong-Xu Liu.

### Writing – original draft: Xiang Li, Yan Lou.

### References

[1] Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol 2020;76:2982–3021.

[2] The Writing Committee of the Report on Cardiovascular Health and Diseases in ChinaReport on cardiovascular health and diseases burden in China: an updated summary of 2020. Chin Circ J 2021;36:521–45.

[3] Li J, Li X, Wang Q, et al. ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data. Lancet 2015;385:441–51.

[4] Yue L, Ju-Ye G, Chang-Geng F, et al. Activating blood circulation herbs for prevention and treatment of coronary heart disease: the evidence and prospect. Chin J Evid Based Med 2018;18:1145–50.

[5] Yue L, Hui-Jun Y, Da-zhuo S, et al. Chinese herb and formulas for promoting blood circulation and removing blood stasis and antiplatelet therapies. Chi Sci Bull 2014;59:647–53.

[6] Yue L, Hui-Jun Y, Da-zhuo S, et al. Chinese herb and formulas for promoting blood circulation and removing blood stasis and antiplatelet therapies. Evid Based Complementary Altern Med 2012;2012.

[7] Banister B, James AT, Alonso A, et al. Joint ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39:119–77.

[8] Wen-Jin Z, Ye C, Yan Z, et al. Current status and prospects of implementing GAP in Chinese medicine injection materials. China J Chin Mater Med 2021;1–9.

[9] Li Y, Zhang J. Improvement and enhancement of traditional Chinese medicine injections. Zhongguo Zhong Yao Za Zhi 2011;36:1905–9.

[10] Zhang XY, Wang YP, Lin LK, et al. Strategy of constructing post-market integral evaluation system of traditional Chinese medicine injection. Zhongguo Zhong Yao Za Zhi 2017;42:3229–32.

[11] Yung HE, Xiaodong LI. Prospects of development of TC Mi injection and suggestions for re-evaluation. J Pharm Res 2021;40:110–4.

[12] Tian J-F, Li J-D, Lei Y, et al. Clinical features of acute myocardial infarction inpatients in 26 level three class A Chinese medicine hospitals in China and the investigation of treatment. Chin J Integr Trad West Med 2012;32:329–32.

[13] Hu X, Liu H-x, Shang J, et al. Research on the clinical characteristics, treatment status and prognosis of inpatients with acute myocardial infarction in level three class A Chinese medicine hospitals in China in 2013. Chin J Integr Trad West Med 2020;40:785–90.

[14] Fan H, Li M, Yu L, et al. Effects of Danhong Injection on platelet aggregation in hyperlipidemia rats. J Ethnopharmacol 2018;212:67–73.

[15] Hu Z, Wang H, Fan G, et al. Danhong injection mobilizes endothelial progenitor cells to repair vascular endothelium injury via upregulating the expression of Akt, eNOS and MMP-9. Phytomedicine 2019;61:152850.

[16] Mao HP, Wang XY, Gao YH, et al. Danhong injection attenuates isoproterenol-induced cardiac hypertrophy by regulating p38 and NF-κB pathway. J Ethnopharmacol 2016;186:20–9.

[17] Zhou ZY, Zhao WR, Zhang J, et al. Sodium tanshinone IIA sulfonate: a review of pharmacological activity and pharmacokinetics. Biomed Pharmacother 2019;118:109362.

[18] Jiang KY, Ruan CG, Gu ZL, et al. Effects of tanshinone II-A sulfonate on adhesion molecule expression of endothelial cells and platelets in vitro. Zhongguo Yao Xie Bao 1998;19:36–40.

[19] Zhu J, Xu Y, Ren G, et al. Tanshinone IIA Sodium sulfonate regulates antioxidant system, inflammation, and endothelial dysfunction in atherosclerosis by downregulation of CLIC1. Eur J Pharmacol 2017;815:427–36.

[20] Wu P, Du Y, Xu Z, et al. Protective effects of sodium tanshinone IIA sulfonate on cardiac function after myocardial infarction in mice. Am J Transl Res 2019;11:351–60.

[21] Chen J, Liu Y, Zeng X, et al. Clinical effects of Danshen lignan extraction combined with atorvastatin calcium tablets in the treatment of senile hypertension and its influence on platelet activation function factors and inflammatory factors. Chin J Integr Med Cardio-Cerebrovasc Dis 2020;18:3384–7.

[22] Xu Jie, Liu De-s. Experimental study on antioxidant stress of Salvia miltiorrhiza lignan extraction in rats with acute myocardial infarction. Clin Lab J (Electron Ed) 2017;6:443–4.

[23] Huang W, Yang Y, Zeng Z, et al. Effect of Salvia miltiorrhiza and lignan extraction on myocardial ischemia/reperfusion and hypoxia/reoxygenation injury. Mol Med Rep 2016;14:4537–44.

[24] Wang ZK, Chen RR, Li JH, et al. Puerarin protects against myocardial ischemia/reperfusion injury by inhibiting inflammation and the NLRP3 inflammasome: the role of the SIRT1/NF-kappaB pathway. Int Immunopharmacol 2020;80:107086.

[25] Pan HP, Yang JZ, Li LL, et al. Experimental study of puerarin injection on the hemorheology in acute blood-stasis model rats. Zhongguo Zhong Yao Za Zhi 2003;28:1178–80.

[26] Yuan Y, Zhou H, Wu QQ, et al. Puerarin attenuates the inflammatory response and apoptosis in LPS-stimulated cardiomyocytes. Exp Ther Med 2016;11:451–20.

[27] Han Y, Wang H, Wang Y, et al. Puerarin protects cardiomyocytes from ischemia-reperfusion injury by upregulating LncRNA ANRIL and inhibiting autophagy. Cell Tissue Res 2021.
[28] Yu Y, Spatz ES, Tan Q, et al. Traditional Chinese medicine use in the treatment of acute heart failure in western medicine hospitals in China: analysis from the China PEACE retrospective heart failure study. J Am Heart Assoc 2019;8:e12776.

[29] Hu J, Zhang HN, Li B, et al. Analysis of adverse events and influencing factors in randomized controlled trials of oral Chinese medicine published in English. Zhongguo Zhong Yao Za Zhi 2020;45:1948–52.

[30] Andrade C. Understanding the basics of meta-analysis and how to read a forest plot: as simple as it gets. J Clin Psychiatry 2020;81:

[31] Mavridis D, Chaimani A, Efthimiou O, et al. Addressing missing outcome data in meta-analysis. Evid Based Ment Health 2014;17:85–9.